Technical Study: AstraZeneca PLC, GlaxoSmithKline PLC, Keryx Biopharma Inc.,
and Raptor Pharma Corp.
Editor Note: For more information about this release, please scroll to bottom
LONDON, October 17, 2013
LONDON, October 17, 2013 /PRNewswire/ --
On Wednesday October 16, 2013, the S&P 500 ended the day at 1,721.54, up
1.38%; the Dow Jones Industrial Average closed at 15,373.83, up 1.36%; and the
NASDAQ Composite finished at 3,839.43, up 1.20%. Shares in the drug
manufacturers - major industry ended mostly on a higher note, tracking gains
in the broader market. The major movers in the industry included AstraZeneca
PLC (NYSE: AZN), GlaxoSmithKline PLC (NYSE: GSK), Keryx Biopharmaceuticals
Inc. (NASDAQ: KERX), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP).
AAAResearchReports.com free coverage on AZN, GSK, KERX, and RPTP is available
upon registration at:
AstraZeneca PLC's stock declined on Wednesday, even as the broader market
finished on a positive note. The company's shares fluctuated between $50.27
and $50.58 before finishing the day 0.28% lower at $50.49. A total of 1.01
million shares were traded, which is below the daily average volume of 1.49
million. The company's shares have gained 1.53% in the previous three months,
underperforming the S&P 500 which has gained 2.70% during the same period.
Further, AstraZeneca PLC's stock is trading above its 200-day moving average
of $49.63. Download free technical research on AZN by signing up at:
Shares in GlaxoSmithKline PLC gained 0.40% on Wednesday, reversing most of the
losses from the previous trading session. The company's shares fluctuated
between $49.97 and $50.32 before ending the day at $50.29. A total of 1.57
million shares were traded, which is below the daily average volume of 2.21
million. The company's shares have gained 0.98% in the previous three trading
sessions, underperforming the S&P 500 which has gained 1.08% during the same
period. Moreover, GlaxoSmithKline PLC's the stock is currently trading above
its 200-day moving average of $49.20. Register now and get access to free
analysis on GSK at:
Keryx Biopharmaceuticals Inc.'s stock rallied on Wednesday, tracking gains in
the broader market. The company's shares finished the day 19.75% higher at
$10.49 after fluctuating between $8.87 and $10.58 during the trading session.
A total of 9.47 million shares were traded, which is significantly above the
daily average volume of 1.99 million. The company's shares have surged 24.81%
in the previous three months and 12.92% in the last one month outperforming
the S&P 500 which has advanced 2.70% and 1.41% during the respective periods.
Furthermore, Keryx Biopharmaceuticals Inc.'s stock is trading near its 52-week
high of $10.92 and also above its 50-day and 200-day moving averages of $9.26
and $7.67, respectively. Sign up and read our complimentary report on KERX at:
Shares in Raptor Pharmaceutical Corp. surged on Wednesday, up 4.80% from the
previous day's closing price of $13.54. The company's shares fluctuated
between $13.55 and $14.20 before ending the day at $14.19. A total of 0.43
million shares were traded, which is below the daily average volume of 0.77
million. The company's shares have gained 34.12% in the previous three months
and 3.50% in the last three trading sessions, compared to a gain of 2.70% and
1.08% in the S&P 500 during the respective periods. Moreover, Raptor
Pharmaceutical Corp.'s stock is currently trading above its 50-day and 200-day
moving averages of $13.38 and $8.45, respectively. The free report on RPTP can
be downloaded by signing up now at:
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However,
we are only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our subscriber
base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us at
5. For any urgent concerns or inquiries, please contact us at
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.